Roche Products Limited
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$96.7M
Doctors Paid
499
Transactions
20,250
2024 Total
$6.1M
Payment Breakdown by Category
Research$94.8M (98.1%)
Consulting$1.2M (1.2%)
Travel$590,093 (0.6%)
Food & Beverage$91,450 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $94.8M | 18,762 | 98.1% |
| Consulting Fee | $1.2M | 496 | 1.2% |
| Travel and Lodging | $590,093 | 467 | 0.6% |
| Food and Beverage | $91,450 | 514 | 0.1% |
| Education | $5,297 | 10 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $300.00 | 1 | 0.0% |
Payments by Type
Research
$94.8M
18,762 transactions
General
$1.9M
1,488 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | $9.2M | 0 | 516 |
| PJIA REGISTRY POST APPROVAL COMMITMENT | $6.4M | 0 | 7 |
| OCRELIZUMAB IN PPMS | $6.3M | 0 | 1,840 |
| TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | $5.8M | 0 | 551 |
| MORPHEUS PANCREATIC | $4.8M | 0 | 285 |
| IMMOTION150 ATEZOLIZUMAB IN RENAL CELL CARCINOMA RCC | $4.4M | 0 | 343 |
| OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | $3.5M | 0 | 981 |
| CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE | $2.8M | 0 | 1,046 |
| Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients with Idiopathic Pulmonary Fibrosis | $2.6M | 0 | 414 |
| A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | $2.5M | 0 | 527 |
| STUDY TO ASSESS EFFICACY SAFETY AND TOLERABILITY IN AMBULATORY BOYS WITH DMD | $2.3M | 0 | 258 |
| A TRIAL TO CHARACTERIZE THE RISK OF QTC PROLONGATION ASSOCIATED WITH RISDIPLAM | $2.1M | 0 | 18 |
| CROHN S DISEASE PROGRAM OLE | $2.1M | 0 | 996 |
| IDASANUTLIN BIOEQUIVALENCE STUDY | $1.9M | 0 | 227 |
| A STUDY OF LONG-TERM EFFECTS OF FENEBRUTINIB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS | $1.9M | 0 | 2 |
| Morpheus UC | $1.9M | 0 | 150 |
| PH1 2 IN ALK REARRANGED NSCLC | $1.8M | 0 | 232 |
| Morpheus pancreatic | $1.8M | 0 | 133 |
| SAFETY AND EFFICACY OF VENETOCLAX FULVESTRANT IN ER POSITIVE METASTATIC BREAST CANCER | $1.8M | 0 | 387 |
| Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | $1.6M | 0 | 4,870 |
| ASCENDING DOSE STUDY IN BOYS WITH DMD | $1.5M | 0 | 116 |
| Ph III OLE Trial to Evaluate Long term Safety and Efficacy of PRM 151 in Patients with IPF | $1.4M | 0 | 197 |
| A Phase 1 Study of KSQ-4279 Alone and In Combination In Patients With Advanced Solid Tumours | $1.4M | 0 | 600 |
| PH III OLE TRIAL TO EVALUATE LONG TERM SAFETY AND EFFICACY OF PRM 151 IN PATIENTS WITH IPF | $1.4M | 2 | 151 |
| CAD11 MAB PH2A B IN RA A TNF IR | $1.3M | 0 | 193 |
| PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | $1.2M | 3 | 140 |
| OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | $1.1M | 0 | 390 |
| PHASE IB STUDY SAFETY PHARMACOL OF MPDL3280A ERLOTINIB OR ALECTINIB IN PATIENTS WITH ADV NSCLC | $1.1M | 0 | 130 |
| PHASE II IN COBIMETINIB ATEZOLIZUMAB WITH PACLITAXOL OR NAV PAC IN PATIENTS WITH METASTATIC TNBC | $1.0M | 0 | 203 |
| MORPHEUS UC | $894,027 | 0 | 51 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Max Rosen, Md Mph, MD MPH | Diagnostic Radiology | Worcester, MA | $225,040 | $0 |
| Nagaraj-Setty Holalkere, Md, MD | Diagnostic Radiology | Boston, MA | $82,205 | $0 |
| Dr. Joseph Volpe, Md, MD | Adolescent Medicine | Boston, MA | $74,232 | $0 |
| Brenda Banwell, Md, MD | Neurology with Special Qualifications in Child Neurology | Baltimore, MD | $58,857 | $0 |
| Karl Kieburtz, Md, MD | Neurology | Rochester, NY | $57,650 | $0 |
| Kevin Winthrop, Md, MD | Infectious Disease | Portland, OR | $51,988 | $0 |
| Gabriel Contreras, Md, Mph, MD, MPH | Nephrology | Miami, FL | $44,240 | $0 |
| Dr. Jeffrey Kaine, Md, MD | Rheumatology | Sarasota, FL | $43,832 | $0 |
| Steven Pipe, Md, MD | Pediatric Hematology-Oncology | Ann Arbor, MI | $36,419 | $0 |
| Dr. Jordan Graff, Md, MD | Ophthalmology | Phoenix, AZ | $35,971 | $0 |
| Sandra Swain, M.d, M.D | Hematology & Oncology | Bethesda, MD | $35,970 | $0 |
| Dr. Arshad Khanani, M.d, M.D | Ophthalmology | Reno, NV | $34,367 | $0 |
| Dr. Nathan Steinle, M.d, M.D | Ophthalmology | Santa Barbara, CA | $30,769 | $0 |
| Dr. Emmanuelle Waubant, M.d, M.D | Neurology | San Francisco, CA | $28,118 | $0 |
| Dr. Dilsher Dhoot, M.d, M.D | Retina Specialist | Santa Barbara, CA | $23,267 | $0 |
| Dr. Carl Awh, M.d, M.D | Ophthalmology | Nashville, TN | $22,891 | $0 |
| Rishi Singh, Md, MD | Ophthalmology | Boston, MA | $22,301 | $0 |
| Dr. Eric Siemers, M.d, M.D | Neurology | Indianapolis, IN | $21,269 | $0 |
| Dr. Fred Lublin, M.d, M.D | Neurology | New York, NY | $21,094 | $0 |
| Jeffrey Bennett, Md, MD | Neurology | Aurora, CO | $20,788 | $0 |
| Dr. Yohei Doi, M.d, M.D | Infectious Disease | Pittsburgh, PA | $20,713 | $0 |
| Matthew Galsky, Md, MD | Medical Oncology | New York, NY | $19,047 | $0 |
| Dr. Isabel Cunningham, M.d, M.D | Hematology | Jamaica, NY | $18,408 | $0 |
| Dr. Marla Dubinsky, M.d, M.D | Specialist | New York, NY | $16,497 | $0 |
| Robert Findling, Md, MD | Child & Adolescent Psychiatry | Cleveland, OH | $16,475 | $0 |
Ad
Top Products
- Actemra $21.8M
- Non-Covered Product $11.4M
Payment Categories
- Food & Beverage $91,450
- Consulting $1.2M
- Travel & Lodging $590,093
- Research $94.8M
About Roche Products Limited
Roche Products Limited has made $96.7M in payments to 499 healthcare providers, recorded across 20,250 transactions in the CMS Open Payments database. In 2024, the company paid $6.1M. The top product by payment volume is Actemra ($21.8M).
Payments were distributed across 66 medical specialties. The top specialty by payment amount is Diagnostic Radiology ($323,299 to 5 doctors).
Payment categories include: Food & Beverage ($91,450), Consulting ($1.2M), Research ($94.8M), Travel & Lodging ($590,093).